MedPath

Indian SEC Recommends Approval for MSN Laboratories' Pitolisant for Narcolepsy

  • The Subject Expert Committee (SEC) in India has recommended granting market authorization to MSN Laboratories for Pitolisant tablets, a generic version of Wakix.
  • The recommendation is contingent upon MSN Laboratories conducting a Phase IV clinical trial and submitting the study protocol to the CDSCO within three months.
  • The SEC noted the limited data on narcolepsy prevalence in India and recognized Pitolisant's novel mechanism of action and the unmet need in treating the condition.
  • The committee also recommended including CYP2D6 genotype determination in the prescribing information before initiating treatment with Pitolisant.
The Subject Expert Committee (SEC) in India has recommended granting market authorization to MSN Laboratories, a Telangana-based pharmaceutical company, for its generic version of Pitolisant tablets. This drug is intended for the treatment of sleep disorders, specifically excessive daytime sleepiness (EDS) or cataplexy in patients with narcolepsy. The decision follows a review of MSN Laboratories' bioequivalence study report, justification for a waiver of a Phase III local clinical trial, and literature data on the prevalence of narcolepsy.
The SEC, which advises the national drug regulator on new drug approvals, made its recommendation during a meeting held on October 29, 2024. The approval is conditional, requiring MSN Laboratories to conduct a Phase IV clinical trial to further evaluate the drug's efficacy and safety in the Indian population. The company must submit the Phase IV study protocol to the Central Drugs Standard Control Organisation (CDSCO) within three months of receiving market authorization.

Unmet Needs in Narcolepsy Treatment

The SEC acknowledged the limited information available regarding the prevalence of narcolepsy in the Indian population. Despite this, the committee recognized that Pitolisant offers a novel mechanism of action compared to existing narcolepsy treatments, addressing an unmet need in this therapeutic area. The committee has recommended that the prescribing information for Pitolisant include the determination of CYP2D6 genotype before initiating treatment.

Patent Landscape and Legal Challenges

Pitolisant is a generic version of Harmony Biosciences' Wakix, a drug protected by a US patent that is set to expire on February 25, 2029. Harmony Biosciences has taken legal action against MSN Laboratories and its US arm, MSN Pharmaceuticals Inc., alleging patent infringement related to the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA). Wakix has achieved significant commercial success, surpassing $2 billion in cumulative net revenue in less than five years. It also holds orphan drug designation for narcolepsy treatment since 2010 and breakthrough therapy designation for cataplexy treatment since 2018.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Panel Approves Sage's Novel Antidepressant for Postnatal Depression, Rejects Alkermes' Treatment

An FDA advisory committee has voted in favor of Sage's Zulresso (brexanolone) for the treatment of postnatal depression, marking a significant step towards its approval as the first specific drug for this condition. However, the same panel rejected Alkermes' ALKS 5461 for major depressive disorder, citing concerns over its benefit-risk profile and trial design.

Nivolumab Recommended for Approval in India for Urothelial Carcinoma

The Subject Expert Committee (SEC) in India recommends nivolumab with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma.

Tonix Pharmaceuticals' TNX-102 SL Shows Promise in Fibromyalgia Treatment

Tonix Pharmaceuticals presented Phase 3 RESILIENT study data, revealing TNX-102 SL significantly reduced fibromyalgia pain versus placebo.

Tonix Pharmaceuticals Seeks FDA Approval for TNX-102 SL in Fibromyalgia

Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, targeting sleep and pain relief in fibromyalgia patients.

Dr. Reddy's Siponimod Tablets Recommended for Marketing Approval in India for SPMS Treatment

Dr. Reddy's Laboratories' Siponimod tablets (0.25 mg, 1 mg, and 2 mg) receive SEC recommendation for market authorization for secondary progressive multiple sclerosis (SPMS) treatment.

Scilex Pharmaceuticals Achieves FDA Agreement on NDA Path for SP-103 in Chronic Neck Pain

Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a lidocaine topical system 5.4%, following a successful end-of-Phase II meeting.

Senex Biotechnology Receives European Patent Allowance for CDK8/19 Inhibitor SNX631-6

Senex Biotechnology received a notice of allowance from the European Patent Office for SNX631-6, a selective CDK8/19 inhibitor, expanding its intellectual property portfolio.

Tonix Pharmaceuticals Submits NDA for TNX-102 SL for Fibromyalgia Treatment

Tonix Pharmaceuticals has submitted an NDA to the FDA for TNX-102 SL, a non-opioid analgesic, seeking approval for fibromyalgia treatment.

Sanbexin Sublingual Tablets Granted FDA Breakthrough Therapy Designation for Ischemic Stroke

Simcere Pharmaceuticals' Sanbexin sublingual tablets receive Breakthrough Therapy designation from the FDA for ischemic stroke treatment.

Scemblix Receives Positive CHMP Opinion for CML Treatment After TKI Failure

The CHMP has recommended marketing authorization for Scemblix (asciminib) for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP).

Reference News

[1]
SEC recommends approval for MSN Laboratories' sleep disorder drug - Pharmabiz.com
pharmabiz.com · Nov 9, 2024

SEC recommends market authorisation for MSN Laboratories' generic Pitolisant tablets for narcolepsy, with conditions inc...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy